Contineum Therapeutics, Inc.
CTNM
$11.43
-$0.10-0.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.59% | -4.06% | -24.59% | -78.04% | -89.97% |
| Total Depreciation and Amortization | 6.41% | 13.33% | 30.65% | 31.67% | 27.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.01% | 106.28% | 63.33% | 239.00% | 2,335.85% |
| Change in Net Operating Assets | -449.63% | -124.78% | -198.88% | -825.36% | -493.45% |
| Cash from Operations | -12.86% | -27.84% | -97.71% | -84.27% | -80.71% |
| Capital Expenditure | -563.83% | 74.70% | -19.51% | 63.03% | 68.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -360.63% | -414.11% | 149.93% | 135.92% | 68.53% |
| Cash from Investing | -363.55% | -405.46% | 149.50% | 135.69% | 70.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 725.00% | 14,458.41% | 147,476.92% | -99.75% | -80.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -225.71% | -- |
| Cash from Financing | 437.50% | 14,458.41% | 146,861.54% | -99.92% | 233.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10,620.87% | 274.00% | 160.13% | -102.77% | -28.59% |